Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Walgreens Boots Alliance Inc. (NASDAQ: WBA) is reportedly close to a $10 billion buyout deal with private equity firm Sycamore Partners, according to The Wall Street Journal. The deal, which could be finalized by Thursday, would take the struggling pharmacy chain private.
Sycamore is expected to offer between $11.30 and $11.40 per share in cash, with potential performance-based incentives. If the acquisition proceeds, Sycamore is likely to retain Walgreens' core U.S. retail operations while divesting or taking public other parts of the company.
Once a dominant force in U.S. pharmacy retail, Walgreens has seen its market value plummet from over $100 billion in 2015 to below $8 billion by late 2024. The company has struggled with declining prescription margins and an unsuccessful push into primary care. Under CEO Tim Wentworth, Walgreens has been closing underperforming stores in an effort to stabilize operations.
Sycamore, known for retail investments like its 2017 acquisition of Staples, aims to reposition Walgreens for long-term growth.
